Cantor Fitzgerald Reiterates “Overweight” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts ...
Cantor Fitzgerald Has Weak Forecast for PACB FY2025 Earnings
Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Pacific Biosciences of California in a note issued to investors on Tuesday, February 18th. Cantor Fitzgerald analyst R. Osborn now ...